KRAS and non-small cell lung carcinoma: The silencing of deoxythymidilate kinase (DTYMK) in the context of LKB1 loss in LKB1/KRAS double mutant non-small cell lung cancer (NSCLC) has been shown to induce synthetic lethality (3).